R-Verapamil - Center Laboratories

Drug Profile

R-Verapamil - Center Laboratories

Alternative Names: Arverapamil - Center Laboratories; CS 02

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center Laboratories
  • Class Antiarrhythmics; Antihypertensives; Antineoplastics; Irritable bowel syndrome therapies; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Melatonin MT1 receptor modulators; Somatostatin receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cluster headache; Type 2 diabetes mellitus

Most Recent Events

  • 01 Oct 2017 Phase-II clinical trials in Type-2 diabetes mellitus (Combination therapy) in Taiwan and USA (PO) (NCT03308695)
  • 10 Oct 2016 R-Verapamil is still in phase II trials for Cluster headache in United Kingdom (PO)
  • 01 Nov 2013 Phase-II clinical trials in Cluster headache in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top